TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26219538

Group type: EXPERIMENTAL
Intervention: FP-Sal novel mDPI 100 μg-50 μg
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: FP-Sal novel mDPI 500 μg-50 μg
Number of subjects: 555

Group type: COMPARATOR
Intervention: FP-Sal novel mDPI
Number of subjects: 555

Group type: COMPARATOR
Intervention: Originator device 100 μg-50 μg
Number of subjects: 555

Group type: COMPARATOR
Intervention: Originator device 500 μg-50 μg
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: FP-Sal novel mDPI and originator device
Number of subjects: 555
Study: 23938309

Group type: EXPERIMENTAL
Intervention: Inhaled apomorphine (mean dose 2.3 mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Inhaled apomorphine
Number of subjects: 55
Study: 21074015

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 0.75 mg, two doses 12 hours apart during the preovulatory phase
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control cycle (untreated)
Number of subjects: 30
Study: 18470753

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16768683

Group type: EXPERIMENTAL
Intervention: Retrograde intramedullary nail fixation (IM group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fixed-angle blade plate fixation (BP group)
Number of subjects: 22
Study: 14651283

Group type: EXPERIMENTAL
Intervention: MTAD (2-h treatment)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: EDTA
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.6% NaOCl
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study: 10807816

Group type: EXPERIMENTAL
Intervention: Salmeterol MDI plus spacer (correct use)
Number of subjects: 20

Group type: COMPARATOR
Intervention: MDI alone (incorrect use)
Number of subjects: 20
Study: 8816295

Group type: EXPERIMENTAL
Intervention: Complex febrile seizures (CFS)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Simple febrile seizures (SFS)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 1428307

Group type: EXPERIMENTAL
Intervention: Partial meniscectomy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Total meniscectomy
Number of subjects: 200
Study: 30623568

Group type: EXPERIMENTAL
Intervention: Philips single‐electric pump, Natural bottle
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Medela Swing single‐electric pump, Calma bottle
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control; vouchers
Number of subjects: 112
Study: 28050988

Group type: EXPERIMENTAL
Intervention: Piezoelectric osteotomy technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rotary osteotomy technique
Number of subjects: 30
Study: 26944385

Group type: EXPERIMENTAL
Intervention: midazolam (0.15 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: tramadol (1 mg/kg)
Number of subjects: 40
Study: 24300544

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 12-week antiretroviral therapy (ART)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 48-week antiretroviral therapy (ART)
Number of subjects: 200
Study: 21986807

Group type: EXPERIMENTAL
Intervention: CHO + PRO
Number of subjects: 14

Group type: COMPARATOR
Intervention: CHO
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CHO + CAF
Number of subjects: 14
Study: 19710187

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for 6 months (EBF6)
Number of subjects: 2951

Group type: COMPARATOR
Intervention: Exclusive breastfeeding for 3 months (EBF3)
Number of subjects: 2951
Study: 18986747

Group type: EXPERIMENTAL
Intervention: SuperSeal
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Gluma
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: MS-Coat
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Copalite Varnish
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study: 15824215

Group type: EXPERIMENTAL
Intervention: Patching (2-6 hours per day) combined with near visual activities and atropine sulfate for children aged 7 to 12 years
Number of subjects: 507

Group type: COMPARATOR
Intervention: Optical correction alone
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Patching (2-6 hours per day) combined with near visual activities
Number of subjects: 507
Study: 12584535

Group type: EXPERIMENTAL
Intervention: Varicella vaccine (2-dose regimen)
Number of subjects: 29
Study: 10586916

Group type: EXPERIMENTAL
Intervention: Chloroquine-resistant isolates (IC50 >= 100 nM) with 16 repeat units in the omega region
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Chloroquine-sensitive isolates (IC50 < 100 nM) with 16 repeat units in the omega region
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Patients with treatment failure infected with parasites carrying 16 repeat units
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Patients showing adequate clinical response with isolates carrying 16 repeat units
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Patients showing adequate clinical response with isolates carrying < or = 15 or > or = 17 repeat units
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sensitivity, specificity, and predictive value of the test
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: In vitro and in vivo resistance to chloroquine
Number of subjects: 75
Study: 8901824

Group type: EXPERIMENTAL
Intervention: Primary aldosteronism
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Renovascular hypertension
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pheochromocytoma
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Essential hypertension
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: All hypertensive groups
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (normotensive subjects and essential hypertension)
Number of subjects: 70
Study: 1806475

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg, p.o.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: GHRH plus placebo (2 tablets, p.o.)
Number of subjects: 14
Study: 6626904

Group type: EXPERIMENTAL
Intervention: Routine antibiotic prophylaxis after urodynamic investigation
Number of subjects: 96

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (implied control)
Number of subjects: 96
Study: 30215342

Group type: COMPARATOR
Intervention: Poor dietary pattern
Number of subjects: 521
Study: 28604824

Group type: EXPERIMENTAL
Intervention: 3TC/FTC
Number of subjects: 33

Group type: COMPARATOR
Intervention: cART
Number of subjects: 33
Study: 27206951

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg subcutaneously every 2 weeks (Q2W)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo subcutaneously every 2 weeks (Q2W)
Number of subjects: 63
Study: 24052500

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 119
Study: 22700527

Group type: EXPERIMENTAL
Intervention: Treatment on days 5 to 10 after hemorrhage
Number of subjects: 2106

Group type: EXPERIMENTAL
Intervention: Coiling treatment on days 5 to 10 after hemorrhage
Number of subjects: 2106

Group type: EXPERIMENTAL
Intervention: Clipping treatment on days 5 to 10 after hemorrhage
Number of subjects: 2106

Group type: EXPERIMENTAL
Intervention: Treatment at 3 to 4 days after hemorrhage
Number of subjects: 2106

Group type: EXPERIMENTAL
Intervention: Treatment at 5 to 10 days after hemorrhage
Number of subjects: 2106

Group type: EXPERIMENTAL
Intervention: Treatment >10 days after hemorrhage
Number of subjects: 2106
Study: 19710213

Group type: EXPERIMENTAL
Intervention: Interventional strategy (clinical monitoring and DUS surveillance every 3 months, followed by PTA for stenosis of 50% or greater)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Interventional strategy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (standard care: clinical and hemodynamic NAF assessment followed by vascular surgeon consultation)
Number of subjects: 108
Study: 17268695

Group type: EXPERIMENTAL
Intervention: rHuEPO and ACE inhibitors/ARBs
Number of subjects: 100

Group type: COMPARATOR
Intervention: rHuEPO with other antihypertensives (calcium channel blockers or beta-adrenergic receptor blockers)
Number of subjects: 100
Study: 15470329

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg single dose)
Number of subjects: 29
Study: 11398172

Group type: EXPERIMENTAL
Intervention: Rectal examination as initial screening test
Number of subjects: 20979

Group type: COMPARATOR
Intervention: PSA screening only (cut-off of 3.0 ng/ml)
Number of subjects: 20979

Group type: COMPARATOR
Intervention: Rectal examination
Number of subjects: 20979
Study: 10339045

Group type: EXPERIMENTAL
Intervention: Care Ambassador intervention (N = 89)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Standard care (N = 82)
Number of subjects: 171
Study: 7992843

Group type: EXPERIMENTAL
Intervention: rPDGF-BB
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2567372

Group type: EXPERIMENTAL
Intervention: Pentamidine mesylate aerosol (4 mg/kg every 2 weeks for the first month then monthly) and zidovudine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pentamidine mesylate aerosol
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pentamidine mesylate aerosol and zidovudine
Number of subjects: 51
Study: 31054551

Group type: EXPERIMENTAL
Intervention: Negative pressure irrigation and suction
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional drainage
Number of subjects: 80
Study: 28110468

Group type: EXPERIMENTAL
Intervention: Increased breakfast eating during treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No change or decrease in daily eating frequency
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline breakfast eating and eating frequency
Number of subjects: 0

Group type: COMPARATOR
Intervention: Changes in eating frequency
Number of subjects: 0
Study: 25540862

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (ICBT)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Internet-delivered behavioral stress management (IBSM)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: ICBT and IBSM
Number of subjects: 158
Study: 23255691

Group type: EXPERIMENTAL
Intervention: Second dose of measles vaccine (study group)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Single dose of measles vaccine (control group)
Number of subjects: 78
Study: 21932660

Group type: EXPERIMENTAL
Intervention: CCLADS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 30
Study: 19050085

Group type: EXPERIMENTAL
Intervention: Pentastarch (500 mL - maximum 3 L or 28 mL x kg(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (blinded)
Number of subjects: 40
Study: 16584102

Group type: EXPERIMENTAL
Intervention: Behavioural Family Therapy (BFT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Individual usual treatment
Number of subjects: 24
Study: 12869126

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (60 sec)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate cord clamping
Number of subjects: 0
Study: 10937953

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 8522716

Group type: EXPERIMENTAL
Intervention: Proximal electrode in the innominate vein position
Number of subjects: 16

Group type: COMPARATOR
Intervention: Proximal electrode in the superior vena cava position
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Proximal electrode in the innominate vein position (normal heart size)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Proximal electrode in the superior vena cava position (normal heart size)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Proximal electrode in the innominate vein position (enlarged heart)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Proximal electrode in the superior vena cava position (enlarged heart)
Number of subjects: 16
Study: 1841044

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg twice daily for 10 days
Number of subjects: 12
Study: 6867623

Group type: EXPERIMENTAL
Intervention: Postoperative urethral catheterisation
Number of subjects: 76

Group type: COMPARATOR
Intervention: Suprapubic cystostomy
Number of subjects: 76
Study: 30779689

Group type: EXPERIMENTAL
Intervention: Shz‐IIV3
Number of subjects: 1599

Group type: COMPARATOR
Intervention: Comparator IIV3
Number of subjects: 1599
Study: 30280390

Group type: EXPERIMENTAL
Intervention: IV SNF472 9 mg kg–1 in HD patients
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo in HD patients
Number of subjects: 28
Study: 28978344

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 0
Study: 26624824

Group type: EXPERIMENTAL
Intervention: Metformin (≤2000 mg/d)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 23988146

Group type: EXPERIMENTAL
Intervention: MS‐MO/UPE
Number of subjects: 26

Group type: COMPARATOR
Intervention: MS‐SO/UPE
Number of subjects: 26
Study: 26086980

Group type: EXPERIMENTAL
Intervention: Enhanced Nurse Family Partnership Study (ENFPS)
Number of subjects: 0
Study: 18941075

Group type: EXPERIMENTAL
Intervention: Matrix-associated autologous chondrocyte transplantation
Number of subjects: 15
Study: 16581161

Group type: EXPERIMENTAL
Intervention: IC41 peptide vaccine
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Poly‐L‐arginine
Number of subjects: 128

Group type: COMPARATOR
Intervention: HCV peptides alone
Number of subjects: 128

Group type: COMPARATOR
Intervention: Poly‐l‐arginine alone
Number of subjects: 128

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 128
Study: 12700622

Group type: EXPERIMENTAL
Intervention: CLA 50:50 (50% c9,t11 CLA and 50% t10,c12 CLA isomers)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: CLA 80:20 (80% c9,t11 CLA and 20% t10,c12 CLA isomers)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sunflower oil fatty acids (reference)
Number of subjects: 71
Study: 11144440

Group type: EXPERIMENTAL
Intervention: docosahexaenoic acid-enriched formula (0.35% of total fatty acids)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: docosahexaenoic acid- (0.36%) and arachidonic acid- (0.72%) enriched formula
Number of subjects: 87

Group type: COMPARATOR
Intervention: commercial formula
Number of subjects: 87

Group type: COMPARATOR
Intervention: human milk
Number of subjects: 87
Study: 9335414

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 7678314

Group type: EXPERIMENTAL
Intervention: Aprotinin (high-dose)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 3741530

Group type: EXPERIMENTAL
Intervention: suprofen sustained release 600 mg tablets
Number of subjects: 60

Group type: COMPARATOR
Intervention: indometacin sustained release 75 mg capsules
Number of subjects: 60
Study: 28732220

Group type: EXPERIMENTAL
Intervention: Surgical removal of impacted mandibular third molars
Number of subjects: 60
Study: 27310329

Group type: EXPERIMENTAL
Intervention: QMF149 (indacaterol maleate/MF, 500/400 μg) via Twisthaler (TH) device with activated charcoal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QMF149 (indacaterol maleate/MF, 500/400 μg) via Twisthaler (TH) device without activated charcoal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indacaterol maleate 300 μg inhaled via Breezhaler (BRZ) device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mouth rinsing after inhalation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study: 24615306

Group type: EXPERIMENTAL
Intervention: 60-minute treatments 2 times weekly
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: 60-minute treatments 3 times weekly
Number of subjects: 228

Group type: COMPARATOR
Intervention: 30-minute treatments
Number of subjects: 228
Study: 23545865

Group type: EXPERIMENTAL
Intervention: Caudal dexmedetomidine (DEX) 0.5 μg/kg and bupivacaine 0.25%, 2.5 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine 2.5 mg/kg and fentanyl 1 μg/kg
Number of subjects: 40
Study: 20152050

Group type: EXPERIMENTAL
Intervention: Ketorolac treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18230015

Group type: EXPERIMENTAL
Intervention: RIDcancerPain
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control
Number of subjects: 176
Study: 16633079

Group type: EXPERIMENTAL
Intervention: Prasugrel 40 mg LD/7.5 mg MD
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg LD/15 mg MD
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo LD/Placebo MD
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Prasugrel 7.5 mg MD
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Prasugrel 15 mg MD
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Prasugrel (both doses)
Number of subjects: 31
Study: 12744408

Group type: EXPERIMENTAL
Intervention: Conventional glass-ionomer (Ketac Bond)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer (Vitremer)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (108 children, 432 teeth)
Number of subjects: 100
Study: 10996520

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8825251

Group type: EXPERIMENTAL
Intervention: Staffed group living situation
Number of subjects: 112

Group type: COMPARATOR
Intervention: Individual apartments
Number of subjects: 112
Study: 1563193

Group type: EXPERIMENTAL
Intervention: AIDS education and anticipatory guidance
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Anticipatory guidance concerning HIV
Number of subjects: 7
Study: 3536770

Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation
Number of subjects: 212

Group type: COMPARATOR
Intervention: Normal care facilities
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 212
Study: 31147964

Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI) system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard surgical instrumentation
Number of subjects: 40
Study: 30040763

Group type: EXPERIMENTAL
Intervention: Water-based exercise (WBE) + Land-based exercises (LBE) (3/week + 2/week for 6 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Land-based exercises (LBE) (5/week for 6 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Water-based exercise (WBE) + Land-based exercises (LBE)
Number of subjects: 60
Study: 26799332

Group type: COMPARATOR
Intervention: TAU (n=23)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TAU+IPT (n=17)
Number of subjects: 40
Study: 24867633

Group type: EXPERIMENTAL
Intervention: ACL reconstruction (ACLR)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Rehabilitation alone
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Any meniscal injury at baseline
Number of subjects: 111
Study: 21863655

Group type: EXPERIMENTAL
Intervention: Sinus Rhythm (SR)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation (AF)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control Group (Healthy Subjects)
Number of subjects: 51
Study: 16195983

Group type: EXPERIMENTAL
Intervention: Salbutamol (SAL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 15
Study: 12360154

Group type: EXPERIMENTAL
Intervention: Rhythm control with electrical cardioversion and antiarrhythmic drugs (amiodarone or other class III agents)
Number of subjects: 1450

Group type: COMPARATOR
Intervention: Rate control with beta-blockers, digoxin, or pacemaker and AV nodal ablation
Number of subjects: 1450
Study: 9549526

Group type: EXPERIMENTAL
Intervention: Training with rhythmic auditory cues
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Training without rhythmic auditory cues
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects (baseline function)
Number of subjects: 30
Study: 7975851

Group type: EXPERIMENTAL
Intervention: Intradermal hepatitis B vaccine (ID-2)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Intramuscular hepatitis B vaccine (IM-10)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Intramuscular hepatitis B vaccine (IM-2)
Number of subjects: 225
Study: 2658853

Group type: EXPERIMENTAL
Intervention: Traditional alarm using a wet sensor mat on the bed attached to an alarm bell out of reach of the child
Number of subjects: 56

Group type: COMPARATOR
Intervention: Mini alarm system incorporating a tiny perineal wet sensor attached to a small alarm worn on the child's clothing
Number of subjects: 56
Study: 805402

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 11963345

Group type: EXPERIMENTAL
Intervention: Counselling session integrating supportive, educational and cognitive‐behavioral components
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Home visits program (5 to 8 visits)
Number of subjects: 859
Study: 30922849

Group type: EXPERIMENTAL
Intervention: Fire-needle acupuncture group (FAG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Filiform-needle acupuncture group (FFAG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Rehabilitation treatment group (RTG)
Number of subjects: 120
Study: 30096441

Group type: EXPERIMENTAL
Intervention: Medication reminder and symptom management intervention (automated system calling daily for medication reminders and weekly for symptom assessment)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 272
Study: 26655583

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 24835901

Group type: EXPERIMENTAL
Intervention: Mastoid dressing (n=17)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-mastoid dressing (n=20)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Mastoid dressing
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-mastoid dressing
Number of subjects: 37